Traditionally, the healthcare system has approached patient care, especially for those with acute conditions and rare diseases, through a lens of sympathy, problem-solving, and normalization. The focus has often been on identifying deficits and developing tools…
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent edema attacks in various parts of the body, including the extremities, face, gastrointestinal tract, and airway. While most current treatments can help relieve acute symptoms…
Takeaways from 2025 Global Digital Transformation Summit Recently, I spoke at the 2025 Global Digital Transformation Summit. The event featured executives from leading companies across the intersection of technology and innovation, and we talked about the…
The FDA’s finalized guidance on Scientific Information on Unapproved Uses (SIUU) marks a pivotal shift for pharmaceutical companies—offering new clarity and flexibility for engaging healthcare providers in compliant, science-based dialogue. In this POV, EVERSANA’s Oncology experts…
The EVERSANA MANAGEMENT CONSULTING team provides an overview of the recent developments and shares their views on the strategic implications for manufacturers. Manufacturers must act decisively to mitigate Most Favored Nation (MFN) exposure through global pricing…
Market access is no longer just a final hurdle—it’s a strategic imperative that shapes how therapies reach the patients who need them most. If you’ve ever wondered what it really takes to bring a treatment from…
In a recent EVERSANA webinar, experts Maneesh Gupta, Jennifer Jennifer Meeuwsen, Anne Marie Robertson, and Iterum Therapeutics CEO Corey Fishman discussed key challenges for first-time biopharma launchers and shared strategies for success. Key challenges: 3x lower…
Building on its commitment to global health innovation and bringing innovators together from around the globe, EVERSANA returns as the Global Host and Presenting Sponsor of Frontiers Health 2025, which will take place November 11-12 in…
Our Pharmacovigilance experts actively track evolving global regulations—so you don’t have to. To help simplify pharmacovigilance, we stay ahead of new regulations, assess their impact on current practices, and recommend actions that empower professionals to update…
Our Pharmacovigilance experts actively track evolving global regulations—so you don’t have to. To help simplify pharmacovigilance, we stay ahead of new regulations, assess their impact on current practices, and recommend actions that empower professionals to update…